Industry News
LCT elated by Huntington's preclinical study
Auckland-based Living Cell Therapies (ASX:LCT) today announced "extraordinary" results from its preclinical trial of alginate-encapsulated pig brain cells in a primate model of Huntington's disease. [ + ]
BresaGen signs two new contracts
Adelaide-based BresaGen (ASX:BGN) has signed two new contracts under its protEcol Services business unit. [ + ]
Biotech summit highlights sector's strong voice
Partnering, collaboration and communication were keenly discussed at the 3rd Australian Biotechnology Summit, held in Sydney last week. Australian of the Year and Clinical Cell Culture (C3) co-founder Fiona Wood led the charge, calling for a solution driven biotech industry. [ + ]
Solbec falls foul of continuous disclosure laws
Perth-based Solbec Pharmaceuticals (ASX:SBP) has paid a AUD$33,000 fine after being issued with an infringement notice by the Australian Securities and Investments Commission (ASIC) for allegedly failing to disclose information to the Australian Stock Exchange (ASX) relating to a drug trial. [ + ]
Endocrine research centre opens at Austin Health
A new research centre to battle diabetes, obesity and osteoporosis, called the Endocrine Centre of Excellence, was opened at Austin Health in Melbourne today. [ + ]
Biotech financial results
Results in Brief: Vertex, Varian, Watson, Chiron, Alcon, Eyetech, Elan, NicOx, MorphoSys, Actelion, AstraZeneca, Shire, GSK, Bristol-Myers Squibb, QLT, Millennium, Celgene, Invitrogen, InterMune, Charles River, Ranbaxy, Takeda, Sankyo, Daiichi, Solvay [ + ]
Cryptome discovers novel compounds to treat cancer
Melbourne biopharma Cryptome's (ASX:CRP) proprietary drug-screening technology has struck a highly prospective vein just 12 months after beginning its first major dig into the human proteome in search of novel anti-cancer drugs. [ + ]
In brief: Peplin, Bone Medical, Probiomics, BioDiem
Peplin (ASX:PEP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement. [ + ]
Cancer Institute NSW
Jim Bishop, CEO of the Cancer Institute NSW, spoke about the state of play at the Institute 18 months after its launch, the progress it has made so far and its plans for the coming year at in Sydney last week. [ + ]
Avastra discontinues Benz Stent project
Sydney biomaterials company Avastra (ASX:AVS) has decided not to exercise its option to acquire the global rights to the Universitaetsklinikum Freiburg's Benz Stent technology. [ + ]
Norwood Immunology patent granted for Russia
Norwood Immunology, a subsidiary of Norwood Abbey (ASX:NAL) has been granted a additional patent relating to its immunology technology for a number of Eurasian territories, including Russia. [ + ]
Chemeq overcomes filtration issue, reveals CEO's salary package
The recent installation of new equipment at antimicrobial specialist Chemeq's (ASX:CMQ) Rockingham manufacturing facility has overcome a filtration issue identified during commissioning of the plant. [ + ]
Apollo adds proteins
Newly listed Sydney biopharma Apollo (ASX:AOP) has added another 10 more human-expressed proteins (HEPs) to its library, bringing its portfolio of provisionally patented proteins to 60. [ + ]
Successful second Sunshine C-Pulse implant
Three days after the death of the first patient to be implanted with its C-Pulse heart-assist pump, Sunshine Heart (ASX:SHC) has announced that a second patient has been successfully implanted with the device in a two-hour operation at New Zealand's Auckland City Hospital. [ + ]
Cytopia trials given FDA OK
The US Food and Drug Administration has approved a clinical trial of Melbourne biopharma Cytopia's (ASX:CYT) promising dual-acting lead anti-cancer molecule CYT997. [ + ]